Search results for:
Ondine Biomedical Leverages Mela Solutions’ 90% NHS ICU Footprint to Advance Commercial Evaluation and Quantify Steriwave® Financial Impact
Strategic data collaboration taps into national critical care software infrastructure across ~4,500 NHS beds to assess rapid hospital ROI, capacity utilisation, and infection reduction. Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies to prevent hospital infections, today announces a strategic data and evaluation collaboration [...]
Five Southern Ontario Hospitals to Deploy Steriwave® Across Approximately 5,000 Annual Surgical Procedures
Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies for the prevention and treatment of hospital infections, announces that five hospitals across Southern Ontario are deploying its Steriwave® nasal photodisinfection to support infection prevention for patients undergoing major orthopaedic and spine surgery. The five hospitals [...]
Hospitales Ángeles Health System Pilots Steriwave® Nasal Photodisinfection in two flagship Mexican Hospitals
Steriwave receives regulatory approval in Mexico Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies for the prevention and treatment of hospital infections, is pleased to announce a partnership with Hospital Ángeles Health System (Grupo Ángeles Servicios de Salud, S.A. de C.V.; "Hospital [...]
Ondine Biomedical Presents Topline Results from Phase 3 LANTERN Trial
This Announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation No. 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended. Upon the publication of this Announcement, this inside information is now considered to be [...]
Major Scottish Hospital Adopts Steriwave
UK's Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies to prevent and treat hospital infections, together with its UK distribution partner, Mölnlycke Health Care, is pleased to announce that NHS Golden Jubilee [...]
Leeds drops SSI 78% over Mupirocin with Steriwave
Published Leeds Study Shows Steriwave® Reduced Surgical Site Infections by 78% versus standard of care using Mupirocin in High Risk Endoscopic Endonasal Skull-Base Surgery Leeds researchers conclude in published study that Steriwave nasal photodisinfection be considered for routine adoption in high risk endoscopic endonasal skull-based surgeries, as data confirms [...]
Nasal Photodisinfection Reduces Surgical Infections in Complex Brain Surgery by 78.5% Compared to Nasal Antibiotics at Leeds Teaching Hospitals
Leeds Drops SSIs by 78.5% in Complex Brain Surgery Interim study results being presented today at ENDOAthens, the 10th World Congress for Endoscopic Surgery of Sinuses, Skull Base, Brain, Spine & Orbit Full study results accepted for publication in The Journal of Laryngology & Otology Ondine Biomedical Inc. (AIM: OBI), [...]
Steriwave ICU Study Outcomes Presented at CSRT2026
SMURF Feasibility Study of Nasal Photodisinfection Presented at National Respiratory Conference Ondine Biomedical Inc. ("Ondine"), a leader in light-activated antimicrobial therapies to prevent and treat hospital infections, announces that results from the SMURF feasibility pilot study ("Suppression of Microbial Burden to Reduce Pneumonia in Critical Illness") were presented at the [...]
Ondine Presented Steriwave Data at IPC 2026
Ondine Biomedical Presented Steriwave Data at Recent Infection Prevention and Control Conference (IPC 2026) Ondine Biomedical Inc. (LON: OBI), a leader in light-activated antimicrobial therapies, announces that its President and Chief Technology Officer, Dr. Nicolas Loebel, was a featured speaker at the Infection Prevention and Control ("IPC") Conference. The event [...]
ICU Study to be Presented at 2026 CACCN Conference
Steriwave ICU Study Findings Selected for Oral Presentation at National Canadian Critical Care Nursing Conference Ondine Biomedical Inc. (AIM: OBI), a global leader in light-activated antimicrobial therapies, announces that the intensive care unit ("ICU") infection study featuring Steriwave® nasal photodisinfection, published in Critical Care on 14 April 2026, has been accepted for both oral [...]
For Media Information
Simon Vane Percy
Amanda Bernard
